Lantan Viatris 500 mg tablete za žvakanje
| Name | Lantan Viatris 500 mg tablete za žvakanje |
|---|---|
| Former Name | Lantan Mylan 500 mg tablete za žvakanje |
| Marketing Authorisation Number | HR-H-708522317 |
| Active Substance | lantan karbonat |
| Composition | jedna tableta za žvakanje od 500 mg sadrži količinu lantan karbonat oktahidrata ekvivalentnu 500 mg lantana |
| Pharmaceutical Form | tableta za žvakanje |
| Manufacturer | McDermott Laboratories Limited, t/a Gerard Laboratories, Dublin 13, Irska Mylan Hungary Kft, Komárom, Mađarska Mylan Germany GmbH , Bad Homburg, Hesse, Njemačka |
| Marketing Authorisation Holder | Viatris Limited, Damastown Industrial Park, Mulhuddart, Dublin, Irska |
| Marketing Authorisation Date | 20.02.2024 |
| MA Period of Validity | 18.01.2026 |
| Classification Number | UP/I-530-09/18-01/218 |
| Registration Number | 381-12-01/171-24-20 |
| Prescription | Medicinal product subject to medical prescription |
| Type of prescription | ponovljivi recept |
| Distribution | Supply through pharmacies (community) |
| Advertising to general public | not allowed |
| ATC Code | V03AE03 |
| Marketing status | stavljeno u promet |
| Shortage status | nema nestašice |
| SmPC | download |
| PL | download |
| Public Assessment Report | download |
| Summary of risk management plan | download |
